3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
9
Active not recruiting
6
Not yet recruiting
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Breast Neoplasms
234
Neoplasms
206
Carcinoma, Non-Small-Cell Lung
100
Colorectal Neoplasms
98
Prostatic Neoplasms
93
Lung Neoplasms
78
Multiple Myeloma
53
Melanoma
51
Pancreatic Neoplasms
50
Head and Neck Neoplasms
49
Neoplasm Metastasis
47
Leukemia, Myeloid, Acute
43
Carcinoma, Hepatocellular
43
Ovarian Neoplasms
39
Brain Neoplasms
39
Squamous Cell Carcinoma of Head and Neck
36
Recurrence
35
Glioblastoma
33
Uterine Cervical Neoplasms
32
Sarcoma
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Glioma
29
Lymphoma, Non-Hodgkin
28
Lymphoma
27
Colonic Neoplasms
27
Stomach Neoplasms
26
Carcinoma, Renal Cell
26
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Rectal Neoplasms
23
Interventions
ponatinib
1
nilotinib
1
asciminib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myeloid, Chronic-Phase
×
90 days
×
Clear all
NCT03874858
2026-04-02
DANTE
Novartis
Phase 2
Completed
124 enrolled
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts